Scarica l'app Stockscreener
108.14
1.79%
-1.97
Dopo l'orario di chiusura:
108.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$110.11
Aprire:
$110.01
Volume 24 ore:
477.94K
Relative Volume:
0.71
Capitalizzazione di mercato:
$5.32B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-16.56
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
+5.00%
1M Prestazione:
-3.63%
6M Prestazione:
+8.64%
1 anno Prestazione:
+49.70%
Intervallo 1D:
$108.14
$111.04
Intervallo di 1 settimana:
$101.41
$111.41
Portata 52W:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
108.14 | 5.07B | 338.46M | -310.96M | -132.82M | -6.53 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
111 Capital Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire Inc.
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report? - Yahoo Finance
Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT - MSN
Two Sigma Advisers LP Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.88 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Oppenheimer Initiates Coverage of Axsome Therapeutics (BMV:AXSM) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Coverage of Axsome Therapeutics (BIT:1AXSM) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Coverage of Axsome Therapeutics (AXSM) with Outperform Recommendation - Nasdaq
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman Sells 3,750 Shares of Stock - MarketBeat
Oppenheimer Initiates Axsome Therapeutics (AXSM) with Outperform Rating - GuruFocus
Axsome Therapeutics Headed for Positive Growth With Ample Pipeline , Oppenheimer Says in New Research - marketscreener.com
Oppenheimer Initiates Coverage on Axsome Therapeutics (AXSM) wit - GuruFocus
Axsome initiated with Outperform at Oppenheimer (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Oppenheimer - MarketBeat
Axsome Therapeutics (AXSM) Gains Positive Outlook with Analyst C - GuruFocus
Oppenheimer Initiates Axsome Therapeutics at Outperform With $185 Price Target - marketscreener.com
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of AXSM, ET and APPS - ACCESS Newswire
Ameriprise Financial Inc. Sells 179,697 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Mark L. Jacobson Sells 20,673 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
Q2 EPS Forecast for Axsome Therapeutics Boosted by Analyst - MarketBeat
Mark L. Jacobson Sells 20,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
How To Trade (AXSM) - news.stocktradersdaily.com
TFG Asset Management GP Ltd Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Trimmed by Wellington Management Group LLP - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for AXSM - Defense World
Hedge Fund and Insider Trading News: Chris Rokos, Ray Dalio, Paul Marshall, Edward Charles Molson, Third Point, Soroban Capital Partners, Whale Rock Capital Management, Elliott Management, Vestis Corp (VSTS), Axsome Therapeutics Inc (AXSM), and - Insider Monkey
Axsome Therapeutics Sets Strong Institutional Presence with Three Elite Healthcare Conference Presentations - Stock Titan
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Nuveen Asset Management LLC Increases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ProShare Advisors LLC Acquires 2,942 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares By Investing.com - Investing.com India
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares - Investing.com Australia
Axsome Therapeutics Secures US$570 Million Financing and Equity Investment from Blackstone - Global Legal Chronicle
Axsome settles patent dispute with Hetero Labs over Sunosi generic - MSN
Axsome Unveils Breakthrough Data from 3 CNS Programs: New Results for Depression, Alzheimer's, and Sleep Disorders - Stock Titan
Axsome, Hetero Settle Patent Fight on Daytime-Sleepiness Drug - Bloomberg Law News
Axsome and Hetero settle patent fight over sleep disorder drug - Endpoints News
Axsome's solriamfetol shows mixed results amid 13 phase III wins in April - BioWorld MedTech
Axsome Therapeutics (AXSM) Resolves Patent Dispute Over Sunosi G - GuruFocus
Axsome Reaches Settlement With Hetero Labs Over Sunosi Patent Dispute; Shares Up Pre-Bell - marketscreener.com
Axsome Therapeutics Settles Sunosi Patent Litigation With Hetero Labs - marketscreener.com
Axsome settles patent lawsuit with Hetero over SUNOSI By Investing.com - Investing.com Nigeria
Axsome settles Sunosi patent dispute with Hetero (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics (AXSM) Settles Patent Dispute Over SUNOSI | - GuruFocus
Axsome Therapeutics Settles Patent Litigation on SUNOSI - TipRanks
Axsome Agrees With Hetero Labs To Settle Patent Litigation Related To SUNOSI - Nasdaq
Axsome settles patent lawsuit with Hetero over SUNOSI - Investing.com
Axsome Therapeutics Enters Settlement with Hetero Labs to Resolve SUNOSI® Patent Litigation - Nasdaq
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):